IL-33 activates two pro-inflammatory factors, secreted IL-6 and IL-23, which lead to the expansion of Th17 cells and imbalance of Th17/Treg cells, ultimately leading to immune dysregulation, promoting the progression of inflammation and also promoting tumor growth in the tumor environment (89). This evidence concerns the gene IL6 and neoplasm.